TuHURA Biosciences And Kintara Therapeutics Announce Phase 1b Trial Of IFx-2.0 In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma And Cutaneous Squamous Cell Carcinoma Results

6/3/24 8:36:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KTRA alert in real time by email

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks

Eighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or avelumab therapy achieved a durable Complete Response (CR), pathologic CR or Partial Response (PR) following IFx-2.0 therapy and rechallenge with an anti-PD(L)-1 checkpoint inhibitor

Data presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Get the next $KTRA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KTRA

Date	Price Target	Rating	Analyst
1/20/2022	$6.00 → $3.00	Buy	HC Wainwright & Co.
9/30/2021	$7.00 → $5.00	Buy	Aegis Capital
9/28/2021	$6.00	Buy	HC Wainwright & Co.

More analyst ratings

$KTRA
Financials

Live finance-specific insights

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, w
10/8/24 7:00:00 AM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments. Recent Corporate Developments Announced that Kintara had entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Merge
5/14/24 4:45:00 PM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunitiesCompanies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ETSAN DIEGO and TAMPA, Fla., April 3, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a bi
4/3/24 7:00:00 AM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger
10/16/24 12:54:00 PM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.
10/16/24 11:58:00 AM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint
10/15/24 4:15:00 PM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care

$KTRA
Market Insights

Live Market Insights

TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves
7/8/24 6:35:50 AM ET
$KA
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
7/1/24 8:37:49 AM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares rose 39.26% to $171.99. The market value of their outstanding shares is at $16.2 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 17.78% to $0.32. The market value of their outstanding shares is at $17.9 million. Solid Biosciences (NASDAQ:SLDB) stock moved upwards by 17.3% to $7.39. The market value of their outstanding shares is at $283.6 million. ASLAN Pharma (NASDAQ:ASLN) stock rose 14.06% to $0.36. The market value of their outstanding shares is at $8.2 million. Alaunos
6/21/24 8:08:00 AM ET
$ASLN
$CASI
$CYCN
$DMTK
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)

Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
5/4/21 8:00:00 AM ET
$KTRA
$ARTL
Biotechnology: Pharmaceutical Preparations
Health Care
Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining, Mirasol Resources and OTC Markets Group
New York, March 03, 2021 (GLOBE NEWSWIRE) -- - Medexus Pharmaceuticals Inc (CVE:MDP) shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results click here - BioPorto A/S (CPH:BIOPOR) expects to complete its clinical study and submit a De Novo application to the US FDA for pediatric use of its NGAL kidney test this summer click here - EVmo Inc (OTCMKTS:YAYO) closes its controlling interest sale to Acuitas Group Holdings click here - Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) brings on Camargo Pharmaceutical Services to boost US FDA approval for Ivectsol click here - Alpine 4 Technologies Ltd (OTCQB:ALPP) appoi
3/3/21 2:25:29 PM ET
$KTRA
$PHUN
Biotechnology: Pharmaceutical Preparations
Health Care
EDP Services
Technology
Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer
SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). "We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication," commented Saiid Zarrabian, Kintara's Chief Executive Officer. "We look forward to working closely with Dr. La
3/3/21 8:00:00 AM ET
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care

TuHURA Biosciences And Kintara Therapeutics Announce Phase 1b Trial Of IFx-2.0 In Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma And Cutaneous Squamous Cell Carcinoma Results

Chat with this insight

Recent Analyst Ratings for $KTRA

$KTRA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Kintara Therapeutics with a new price target

Aegis Capital reiterated coverage on Kintara Therapeutics with a new price target

HC Wainwright & Co. initiated coverage on Kintara Therapeutics with a new price target

$KTRA Financials

Live finance-specific insights

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement

$KTRA SEC Filings

SEC Form EFFECT filed by Kintara Therapeutics Inc.

Kintara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$KTRA Large Ownership Changes

This live feed shows all institutional transactions in real time.

$KTRA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$KTRA Press Releases

Fastest customizable press release news feed in the world

SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

SEC Form SC 13G filed by Kintara Therapeutics Inc.

SEC Form SC 13G/A filed by Kintara Therapeutics Inc. (Amendment)

SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis

New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)

SEC Form 4 filed by Director Ng George K

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

$KTRA Market Insights

Live Market Insights

TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

12 Health Care Stocks Moving In Friday's Pre-Market Session

$KTRA Leadership Updates

Live Leadership Updates

Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining, Mirasol Resources and OTC Markets Group

Kintara Therapeutics Appoints Dr. Mario Lacouture to Scientific Advisory Board for Cutaneous Metastatic Breast Cancer

Recent Analyst Ratings for
$KTRA

$KTRA
Analyst Ratings

$KTRA
Financials

$KTRA
SEC Filings

$KTRA
Large Ownership Changes

$KTRA
Insider Trading

$KTRA
Press Releases

$KTRA
Market Insights

$KTRA
Leadership Updates